Видео ютуба по тегу Abt-199

Dr. Younes on IPI-145 and ABT-199 in Lymphoid Malignancies
Dr. Younes on IPI-145 and ABT-199 in Lymphoid Malignancies
Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas
Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas
Side-effects profile of venetoclax (ABT-199)
Side-effects profile of venetoclax (ABT-199)
Prof. John Gribben describes Deborah's clinical trial: venetoclax (ABT-199) plus obinutuzumab
Prof. John Gribben describes Deborah's clinical trial: venetoclax (ABT-199) plus obinutuzumab
Dr. Brown Gives an Overview of ABT-199 for the Treatment of CLL
Dr. Brown Gives an Overview of ABT-199 for the Treatment of CLL
How venetoclax (ABT-199) targets and kills CLL cells
How venetoclax (ABT-199) targets and kills CLL cells
Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma
Dr. John Seymour on the Efficacy of ABT-199 in High-Risk CLL
Dr. John Seymour on the Efficacy of ABT-199 in High-Risk CLL
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL
The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL
The first consultation before starting treatment with venetoclax (ABT-199)
The first consultation before starting treatment with venetoclax (ABT-199)
The use of venetoclax (ABT-199) in the treatment of CLL
The use of venetoclax (ABT-199) in the treatment of CLL
Mechanism of action of venetoclax (ABT-199) and its side effects
Mechanism of action of venetoclax (ABT-199) and its side effects
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
Venotoclax (ABT-199/GDC-0199) i with Decitabine or Azacitidine in Patients with AML
Venotoclax (ABT-199/GDC-0199) i with Decitabine or Azacitidine in Patients with AML
Dr Barbara Eichhorst at ASH 2014: ABT-199 monotherapy and combination trials in CLL
Dr Barbara Eichhorst at ASH 2014: ABT-199 monotherapy and combination trials in CLL
Dr. Younes on IPI-145 and ABT-199 for Lymphoid Malignancies
Dr. Younes on IPI-145 and ABT-199 for Lymphoid Malignancies
Oncotarget | ABT199/Venetoclax in Acute Myeloid Leukemia Treatment
Oncotarget | ABT199/Venetoclax in Acute Myeloid Leukemia Treatment
ABT199/Venetoclax Synergism with Thiotepa Enhances AML Cytotoxicity | Oncotarget
ABT199/Venetoclax Synergism with Thiotepa Enhances AML Cytotoxicity | Oncotarget
ASH 2014: Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
ASH 2014: Preliminary results of a phase Ib study combining ABT-199 and obinutuzumab in CLL
Targeting the survival cascade of B-cells in lymphoid malignancies
Targeting the survival cascade of B-cells in lymphoid malignancies
Bok Docking ABT-199
Bok Docking ABT-199
Introducing venetoclax, a powerful new drug that may treat CLL
Introducing venetoclax, a powerful new drug that may treat CLL
Deborah’s story: ABT and Me
Deborah’s story: ABT and Me
Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial
Venetoclax dose-escalation and obinutuzumab treatment schedule in a clinical trial